Sirolimus API

Sirolimus / Rapamycin for facial angiofibromas

A Sirolimus vaseline® 0.1% jelly produced by pharmacies according to an prescription shows success in the treatment of facial angiofibromas.

Facial angiofirbomas are a symptom of tuberous sclerosis (TSC also Pringle-Bourneville disease). Tuberous sclerosis is a multi-system disease. At least for the treatment of facial angiofibromas, a rapamycin vaseline® jelly helps!

TSC is caused by inactivating mutations on the TSC-1 or TSC2 gene. These two genes play an important role in the regulation of phosphoinostide-3-kinase (PI3K) and the inhibition of the enzyme mTOR.

A 0.05 or 0.1% Sirolimus valselin® jelly should be sufficient for a first therapy attempt.

Cfm Oskar Tropitzsch GmbH offers Sirolimus / Rapamycin as an EU API according to AMG / AMWHV in 5g packaging customary for pharmacies.

More news